March 2020 Briefing - HIV & AIDS

Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for March 2020. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Doctors, Hospitals, Pharmacies Warned Not to Stockpile Meds

TUESDAY, March 31, 2020 (HealthDay News) -- In a joint statement released by the American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists, the professional groups "strongly oppose" physicians, pharmacies, and hospitals prophylactically prescribing medications or purchasing excessive amounts or stockpiles of potential treatments for COVID-19.

Joint Statement

U.S. Army Opens Field Hospital in New York City

MONDAY, March 30, 2020 (HealthDay News) -- The first U.S. Army field hospital for civilian patients opened in New York City Monday and could be the first of many across the nation as it struggles with the coronavirus pandemic.

CBS News Article
More Information

PPE Negative for SARS-CoV-2 After Patient Contact

FRIDAY, March 27, 2020 (HealthDay News) -- Samples collected from personal protective equipment (PPE) from health care workers (HCWs) caring for patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were negative for SARS-CoV-2, according to research published online March 26 in Infection Control & Hospital Epidemiology.

Abstract/Full Text

Workers at Risk for COVID-19 Exposure Can Access Online Training

THURSDAY, March 26, 2020 (HealthDay News) -- The National Institutes of Health has launched a new website with educational resources for hospital employees, emergency first responders, and other workers at risk for exposure to COVID-19.

More Information

Fostemsavir Active in Multidrug-Resistant HIV-1 Infection

THURSDAY, March 26, 2020 (HealthDay News) -- Among patients with multidrug-resistant HIV-1 infection who have limited therapy options, reductions in HIV-1 RNA level were significantly greater in those who received fostemsavir compared with placebo during the first eight days, according to a study published in the March 26 issue of the New England Journal of Medicine.

Abstract/Full Text (subscription or payment may be required)

National Health Spending Expected to Increase Through 2028

WEDNESDAY, March 25, 2020 (HealthDay News) -- National health expenditures are projected to increase at an average annual rate of 5.4 percent for 2019 to 2028, representing almost 20 percent of U.S. gross domestic product by 2028, according to a study published online March 24 in Health Affairs.

Abstract/Full Text (subscription or payment may be required)

Serial Interval of COVID-19 Estimated at 3.96 Days

FRIDAY, March 20, 2020 (HealthDay News) -- The serial interval of coronavirus 2019 (COVID-19), defined as the time between a primary case and secondary case developing symptoms, is 3.96 days, according to a study published online March 19 in Emerging Infectious Diseases, a publication of the U.S. Centers for Disease Control and Prevention.

Abstract/Full Text

Hep C Testing, Treatment Rates Low at Federally Qualified Health Centers

FRIDAY, March 13, 2020 (HealthDay News) -- The rates of hepatitis C virus (HCV) testing and treatment initiation are low at federally qualified health centers (FQHC) in the United States, according to a study published online March 4 in the Journal of General Internal Medicine.

Abstract/Full Text (subscription or payment may be required)

Second Case of HIV-1 Cure After Stem Cell Transplant Reported

THURSDAY, March 12, 2020 (HealthDay News) -- A second case of HIV-1 cure following allogeneic hemopoietic stem cell transplantation has been reported at 30 months after analytical treatment interruption (ATI), according to a study published online March 10 in The Lancet HIV.

Abstract/Full Text
Editorial

New HIV PrEP Drug Not Cost-Effective Compared With Generic

WEDNESDAY, March 11, 2020 (HealthDay News) -- Use of tenofovir alafenamide-emtricitabine (F/TAF) is not cost-effective compared with generic tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) among men who have sex with men (MSM), according to a study published online March 10 in the Annals of Internal Medicine.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

2018 Health Care Spending Up Due to Higher Prices

MONDAY, March 9, 2020 (HealthDay News) -- Average employer-sponsored insurance spending rose to $5,892 per person in 2018, according to the Health Care Cost Institute annual Health Care Cost and Utilization Report.

Health Care Cost and Utilization Report

Long-Acting Cabotegravir, Rilpivirine Noninferior in HIV-1

THURSDAY, March 5, 2020 (HealthDay News) -- For patients with HIV-1 suppression, long-acting cabotegravir plus rilpivirine is noninferior to oral therapy with dolutegravir-abacavir-lamivudine and standard oral therapy, according to two studies published online March 4 in the New England Journal of Medicine.

Abstract/Full Text - Orkin (subscription or payment may be required)
Abstract/Full Text - Swindells (subscription or payment may be required)
Editorial (subscription or payment may be required)

Female Clinical Chairs Paid Significantly Less Than Men

THURSDAY, March 5, 2020 (HealthDay News) -- There are significant sex differences in salaries of clinical department chairs in public medical schools in the United States, according to a research letter published online March 2 in JAMA Internal Medicine.

Abstract/Full Text (subscription or payment may be required)

Racial/Ethnic Insurance Coverage Disparity Down Since ACA

WEDNESDAY, March 4, 2020 (HealthDay News) -- Since the implementation of coverage expansions associated with the Affordable Care Act (ACA), the disparities in insurance coverage related to race and ethnicity have decreased, according to a study published in the March issue of Health Affairs.

Abstract/Full Text (subscription or payment may be required)

Considerable Increase Seen in List, Net Prices of Branded Drugs

WEDNESDAY, March 4, 2020 (HealthDay News) -- From 2007 to 2018, there were substantial increases in list and net prices of branded drugs in the United States, according to a study published in the March 3 issue of the Journal of the American Medical Association.

Abstract/Full Text (subscription or payment may be required)
Editorial 1 (subscription or payment may be required)
Editorial 2 (subscription or payment may be required)

1996 to 2016 Saw Increases in U.S. Spending on Health Care

TUESDAY, March 3, 2020 (HealthDay News) -- From 1996 to 2016, there were considerable increases in U.S. spending on health care, according to a study published in the March 3 issue of the Journal of the American Medical Association.

Abstract/Full Text (subscription or payment may be required)

Related Stories

No stories found.
logo
www.healthday.com